BIIB Stock Biogen Inc.
BUY US · NasdaqGSUpgraded on approaching pipeline readouts and a supportive institutional ownership base.
Future value: $247.32 (-1.96%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Truist and Wolfe upgrades ahead of major data catalysts.
- ▸Above 50-day MA (+12.5%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (98.2% of range) — strength
- ▾Trading above its price target — limited upside
Is BIIB a buy right now?
Trend: BIIB is trading above the 50-day average (+12.50%), RSI 45 — neutral momentum, with a 3-month return of +22.69%.
Valuation & quality: Biogen Inc. trades on a trailing P/E of 44.8, forward P/E 15.3, PEG 2.58, price-to-book 1.98; fundamentals show net margin 8.3%, return on equity 4.6%, revenue growth 3.4% year on year.
Analyst consensus: 32 analysts have a mean 12-month price target of $247.32 (-2% vs the last close; range $175.00 – $310.00), consensus rating “buy”.
Our screen: BUY (score 3) — Upgraded on approaching pipeline readouts and a supportive institutional ownership base.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -4.40% | +3.20% | +3.60% | +10.20% | -6.10% | +6.80% | +4.30% | +11.70% |
Fundamentals
Analyst price target
Technical signals
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Sector: Healthcare · Industry: Drug Manufacturers - General · United States · 7,500 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.